Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Masson D, Denis MG, Lustenberger P. Limitations of CD44v6 amplification for the detection of tumour cells in the blood of colorectal cancer patients. Br J Cancer 2000;82:1283-9. [PMID: 10755402 PMCID: PMC2374479 DOI: 10.1054/bjoc.1999.1092] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open

For:	Masson D, Denis MG, Lustenberger P. Limitations of CD44v6 amplification for the detection of tumour cells in the blood of colorectal cancer patients. Br J Cancer 2000;82:1283-9. [PMID: 10755402 PMCID: PMC2374479 DOI: 10.1054/bjoc.1999.1092] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open

Number

Cited by Other Article(s)

Belthier G, Homayed Z, Grillet F, Duperray C, Vendrell J, Krol I, Bravo S, Boyer JC, Villeronce O, Vitre-Boubaker J, Heaug-Wane D, Macari-Fine F, Smith J, Merlot M, Lossaint G, Mazard T, Portales F, Solassol J, Ychou M, Aceto N, Mamessier E, Bertucci F, Pascussi JM, Samalin E, Hollande F, Pannequin J. CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM. Cancers (Basel) 2021;13:cancers13194966. [PMID: 34638450 PMCID: PMC8508506 DOI: 10.3390/cancers13194966] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 09/24/2021] [Accepted: 09/27/2021] [Indexed: 12/15/2022] Open

Abstract

Simple Summary

In the present work, we describe (for the first time) the use of the transmembrane protein, CD44v6, to detect CTCs from blood samples of several patients with colorectal or breast cancer. We used CD44v6 antibodies to demonstrate that live CTCs can be specifically purified from CRC patient blood samples via magnetic bead- or FACS-based isolation techniques. Finally, we demonstrated that CD44v6-positive CTCs rarely expressed EpCam, which is currently the gold standard to enumerate CTCs, suggesting the need to use a combination of markers for a more comprehensive view of CTC heterogeneity.

Abstract

Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting and isolating CTCs remains sub-optimal because they are currently largely identified by epithelial markers such as EpCAM. New, complementary CTC surface markers are therefore urgently needed. We previously demonstrated that a splice variant of CD44, CD44 variable alternative exon 6 (CD44v6), is highly and specifically expressed by CTC cell lines derived from blood samples in colorectal cancer (CRC) patients. Two different approaches—immune detection coupled with magnetic beads and fluorescence-activated cell sorting—were optimized to purify CTCs from patient blood samples based on high expressions of CD44v6. We revealed the potential of the CD44v6 as a complementary marker to EpCAM to detect and purify CTCs in colorectal cancer blood samples. Furthermore, this marker is not restricted to colorectal cancer since CD44v6 is also expressed on CTCs from breast cancer patients. Overall, these results strongly suggest that CD44v6 could be useful to enumerate and purify CTCs from cancers of different origins, paving the way to more efficacious combined markers that encompass CTC heterogeneity.

Collapse

Affiliation(s)

Guillaume Belthier Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.)
Zeinab Homayed Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.)
Fanny Grillet Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.)
Christophe Duperray Cytometry IRMB, Montpellier Rio Imaging, 34090 Montpellier, France;
Julie Vendrell Department of Pathology and Onco-Biology, CHU Montpellier, 34295 Montpellier, France; (J.V.); (J.S.)
Ilona Krol Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; (I.K.); (N.A.)
Sophie Bravo Laboratoire de Biochimie, CHU Carémeau, 30900 Nîmes, France; (S.B.); (J.-C.B.)
Jean-Christophe Boyer Laboratoire de Biochimie, CHU Carémeau, 30900 Nîmes, France; (S.B.); (J.-C.B.)
Olivia Villeronce Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.)
Jihane Vitre-Boubaker Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.)
Diana Heaug-Wane Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.)
Françoise Macari-Fine Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.)
Jai Smith Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne, Melbourne, VIC 3010, Australia; (J.S.); (F.H.) University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, VIC 3010, Australia
Matthieu Merlot Medical Oncology Department, Institut du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France; (M.M.); (G.L.); (T.M.); (F.P.); (M.Y.)
Gérald Lossaint Medical Oncology Department, Institut du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France; (M.M.); (G.L.); (T.M.); (F.P.); (M.Y.)
Thibault Mazard Medical Oncology Department, Institut du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France; (M.M.); (G.L.); (T.M.); (F.P.); (M.Y.)
Fabienne Portales Medical Oncology Department, Institut du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France; (M.M.); (G.L.); (T.M.); (F.P.); (M.Y.)
Jérôme Solassol Department of Pathology and Onco-Biology, CHU Montpellier, 34295 Montpellier, France; (J.V.); (J.S.) Montpellier Research Cancer Institute (IRCM), INSERM U1194, University of Montpellier, 34298 Montpellier, France
Marc Ychou Medical Oncology Department, Institut du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France; (M.M.); (G.L.); (T.M.); (F.P.); (M.Y.)
Nicola Aceto Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; (I.K.); (N.A.)
Emilie Mamessier Predictive Oncology Laboratory, Cancer Research Center of Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université, 13009 Marseille, France; (E.M.); (F.B.)
François Bertucci Predictive Oncology Laboratory, Cancer Research Center of Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université, 13009 Marseille, France; (E.M.); (F.B.)
Jean Marc Pascussi Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.)
Emmanuelle Samalin Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.) Medical Oncology Department, Institut du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France; (M.M.); (G.L.); (T.M.); (F.P.); (M.Y.)
Frédéric Hollande Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne, Melbourne, VIC 3010, Australia; (J.S.); (F.H.) University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, VIC 3010, Australia
Julie Pannequin Institute of Functional Genomics (IGF), UMR5203 CNRS, U1191 INSERM and UM, 34094 Montpellier, France; (G.B.); (Z.H.); (F.G.); (O.V.); (J.V.-B.); (D.H.-W.); (F.M.-F.); (J.M.P.); (E.S.) Correspondence:

Collapse

Immunohistochemistry. MODERN SURGICAL PATHOLOGY 2009. [PMCID: PMC7151845 DOI: 10.1016/b978-1-4160-3966-2.00016-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]

Katsumata K, Sumi T, Mori Y, Hisada M, Tsuchida A, Aoki T. Detection and evaluation of epithelial cells in the blood of colon cancer patients using RT-PCR. Int J Clin Oncol 2007;11:385-9. [PMID: 17058136 DOI: 10.1007/s10147-006-0590-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2005] [Accepted: 05/25/2006] [Indexed: 11/24/2022]

Development of a Facile Fluorescent Assay for the Detection of 80 Mutations Within the p53 Gene. Mol Med 2002. [DOI: 10.1007/bf03402148] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open

Tsavellas G, Patel H, Allen-Mersh TG. Detection and clinical significance of occult tumour cells in colorectal cancer. Br J Surg 2001;88:1307-20. [PMID: 11578283 DOI: 10.1046/j.0007-1323.2001.01863.x] [Citation(s) in RCA: 82] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]

Hodgson DR, Clayton SJ, Girdler F, Brotherick I, Shenton B, Browell D, Stuart M, Fox JC, Ceuppens P, Foy CA, Whitcombe D, Gibson NJ. ARMS™ Allele-specific Amplification-based Detection of Mutant p53 DNA and mRNA in Tumors of the Breast. Clin Chem 2001. [DOI: 10.1093/clinchem/47.4.774] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]